CRT-718 Early In Vivo Evaluation of Strut Healing Following Bioresorbable Polymer Everolimus Eluting Stent Implantation in Humans: The TIMELESS Study  by Granada, Juan F. et al.










Sis Target Lesion Failure (TLF) at 6-month for cohort 1 and at 12-month for cohort 2.
For some patients also 18-month and 24-month imaging data are available.
RESULTS TLF rate at 36-month was 6.8% including 2 TLRs and 1 peri-procedural MI
occurring at the 12-month follow-up angiography; no events emerged from 12- to
36-month. No cardiac death or scaffold thrombosis was observed.
Vasoconstriction after acetylcholine at 6-month (delta¼-10.04%; p¼0.0008 versus
baseline) followed by vasodilatation after nitroglycerine(delta¼8.69%; p<0.0001
versus baseline) demonstrates the uncaging aspect of the absorption process with no
further change at the 12-month follow-up. Six-month virtual histology (VH) data
showed a signiﬁcant decrease in the dense calcium by 39.5% (p¼0.0015) remaining
stable from 6- to 12-month follow-up. This decrease is interpreted as a surrogate
assessment for the bioabsorption process of the scaffold material.
Echogenicity data using the decrease in intensity of the ultrasound signal to
quantify the change in strut structure demonstrate a continuous decrease in %
hyperechogenicity over the follow-up period, with the most pronounced changes
within the ﬁrst 6 months (22 to 16% p<0.001).
CONCLUSION DREAMS shows excellent safety and efﬁcacy data with no death and no
scaffold thrombosis up to 3 years in the BIOSOLVE-I trial. Multi-modality imaging
documented the absorption process and the uncaging aspect of this device already at
6 months.
CRT-716
Six-month Revascularization Outcome Of Jetstream Atherectomy In Treating
In-stent Restenosis Of Femoropopliteal Arteries: Results Of The Jetstream-ISR
Study
Nicolas W. Shammas,1 Gail Shammas,1 Subhash Banerjee,2 Jeffrey J. Popma,3
Atif Mohammad,2 Michael Jerin4
1Midwest cardiovascular Research Foundation, Davenport, IA; 2VA Medical Center,
Dallas, TX; 3Beth Israel Deaconess Medical Center, Boston, MA; 4St Ambrose
University, Davenport, IA
BACKGROUND Treatment of in-stent restenosis (ISR) of the femoropopliteal (FP)
artery is complex and is associated with high rate of restenosis. Debulking of FP ISR
lesions have been attempted to reduce restenotic tissue burden and improve patency
or target lesion revascularization (TLR). Recently laser atherectomy of FP ISR was
shown to reduce target lesion revascularization at 6 months when compared to plain
old balloon angioplasty (POBA) alone.
JetStream Atherectomy (JS) is a rotational cutter with aspiration capacity that has
been shown to cut and remove atherosclerotic and restenotic tissue. Its application
within a stented FP artery is off label. In this study, JS Navitus L or XC was applied
prospectively in a cohort of FP ISR from 2 centers to evaluate acute procedural and
6-month outcomes and stent-device interaction. Data on 40 infrainguinal ISR lesions
treated with the older generation Pathway PV atherectomy system were previously
reported from Europe and no safety concerns were raised. The primary patency rate,
however, was low at 33 % after 12 months. Since then, the device was upgraded to the
JetStream Navitus with enhanced cutting ability and aspiration. This is the ﬁrst
prospective report on the off label use of the Jetstream Navitus XC atherectomy de-
vice in treating FP ISR (clinicaltrials.gov identiﬁer NCT01722877).
METHODS 29 patients (32 limbs) with FP ISR were treated at 2 medical centers by 2
operators from October 2012 to August 2014. Patients were consented prior to the
procedure and were included in the study only if they were found to have an in-stent
restenotic lesion in the FP segment. The Jetstream device was used as a ﬁrst modality
of treatment. No other debulking devices, cutting/scoring balloons or cryogenic bal-
loons were allowed. Adjunctive treatment was limited to POBA using a semi or non-
compliant peripheral vascular balloon or stenting only if signiﬁcant residual nar-
rowing (>30%) remained or a signiﬁcant dissection (type C or higher) was seen. It was
recommended that the Jetstream be used to maximize debulking until the residual
stenosis  50% prior to adjunctive therapy. The study was approved by the Institu-
tional Review Board (IRB) at both institutions. Demographics, clinical, procedural and
angiographic variables were prospectively collected. Quantitative vascular angiog-
raphy was performed on lesions at baseline, post atherectomy alone and post
adjunctive treatment. Six-month follow up was achieved on all patients (except 3 atthe time of this writing). In-hospital and 6-month major adverse events were recor-
ded. The primary effectiveness endpoint was acute procedural success deﬁned as
obtaining angiographically  30% residual narrowing with no serious adverse events
at the end of the procedure. The primary safety endpoint was major adverse events
in-hospital and at 6 months which included device-induced vascular injury as re-
ported by the operator, amputation (major and minor unplanned), death, signiﬁcant
distal embolization requiring the use of pharmacologic or mechanical means to treat
(other than a vasodilator), perforation, major bleeding, myocardial infarction as
deﬁned by ACC criteria, stroke, access complications (AV ﬁstula and pseudoaneur-
ysm), acute renal failure and acute ( 24 hours) or subacute (than 24 hours) vessel
closure. Secondary endpoints included acute device success deﬁned as a residual
narrowing of  50% by the JetStream device alone and before adjunctive treatment
and with no serious adverse events, distal embolization, clinically driven TLR and
TVR at 6-month follow up based on symptom recurrence, ankle brachial indices (ABI),
Rutherford- Becker class at one month and 6 month, death, and amputation. Device-
stent untoward interaction was evaluated by an independent angiographic core lab-
oratory. Descriptive analysis was done on all variables. Continuous variables were
presented as mean  SD and dichotomous variables as percentages. Kaplan-Meier
survival curve for TLR was plotted.
RESULTS 29 consecutive patients (32 limbs) (mean age 72.5  11.1 years, 34.5% males)
were included in the study. One patient withdrew from the study. Six-month follow-
up was completed on 25 patients. Adjunctive balloon angioplasty was performed in
100% at a mean pressure of 12.2  3.2 atm. Lesion length was 16.6  12 cm and total
treated length 23.7  18.8 cm. Acute procedural success occurred in 100% of patients.
Acute device success was 75.8%. Embolic ﬁlter protection (EFP) was used in 16/32
(50.0%) of limbs. Macrodebris was noted in 2/16 (12.5%) of ﬁlters and distal emboli-
zation (DE) requiring treatment was 9.4% (2 with no EFP (one after adjunctive PTA), 1
with Spider EFP, 0 with Nav-6 EFP). There were no new stent fractures (n¼24) post JS
as reported by Core Lab analysis. On 6-month follow-up TLR occurred in 14.3%
(Figure 1), patency rate (PSVR<2.4) 16/23 (70%), total death 4% (1/25), vascular related
death 0%, major bleeding 0%.
CONCLUSION JS atherectomy using the Navitus device has favorable acute results in
treating in-stent restenosis of the FP arteries with no device-stent interaction and
high procedural success. At 6-month follow-up TLR compares favorably to historic
controls from balloon angioplasty or other atherectomy devices. A multicenter ran-
domized trial is needed to conﬁrm these results.
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Bioresorbable polymer DES technologies promise to enhance vascular healing by
reducing the polymer exposure to the vessel wall potentially allowing the earlier
discontinuation of dual anti-platelet therapy. At the present time, the in vivo early
vascular healing response to this type of technologies is still unclear. The TIMELESS
study is a multi-center, prospective, single arm study enrolling real world patients
undergoing PCI. All patients underwent Synergy stent implantation (Boston Scientiﬁc
Corp, MA, USA) using the Element Platinum-chromium platform coated with an ultra-
thin abluminal bioabsorbable PLGA polymer eluting Everolimus. At 3 months, all
patients underwent OCT imaging and Clopidogrel was stopped regardless of the OCT
ﬁndings. A total of 37 patients were included in the study. The majority of the pa-
tients underwent PCI due to acute coronary syndromes (w65%). The mean vessel
reference diameter was 2.63  0.40 mm and 67.5% of the cases received stents longer
than 20 mm in length. At 3 months, angiographic follow up showed a percentage
diameter of stenosis of 8.1%  7.5% and an angiographic late loss of 0.03  0.24 mm. A
total of 7,761 struts (209.9  45.8 struts per stent) were analyzed using OCT imaging.
Full OCT analysis will be available at the time of the presentation.
